Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has
progressed after standard chemotherapy. Patients will receive gallium nitrate 300 mg/m2/day
by continuous IV infusion for 7 consecutive days using a portable infusion pump.
Hospitalization is not required. Stable or responding patients will receive additional
gallium nitrate infusions every 3 weeks until the time of disease progression, for a maximum
total of 8 infusions, or 2 cycles after complete remission has been documented.